J
Jama M. Darling
Researcher at University of North Carolina at Chapel Hill
Publications - 32
Citations - 1904
Jama M. Darling is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Hepatitis C & Sofosbuvir. The author has an hindex of 13, co-authored 30 publications receiving 1586 citations.
Papers
More filters
Journal ArticleDOI
Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study
Naga Chalasani,Herbert L. Bonkovsky,Robert J. Fontana,William M. Lee,Andrew Stolz,Jayant A. Talwalkar,K. Rajendar Reddy,Paul B. Watkins,Victor J. Navarro,Huiman X. Barnhart,Jiezhun Gu,Jose Serrano,Jawad Ahmad,Nancy Bach,Meena B. Bansal,Huiman X. Barnhart,Kimberly L. Beavers,Herbert L. Bonkovsky,Francisco O. Calvo,Charissa Y. Chang,Hari S. Conjeevaram,Gregory E. Conner,Jama M. Darling,Ynto S. de Boer,Douglas T. Dieterich,Frank DiPaola,Francisco A. Durazo,James E. Everhart,Robert J. Fontana,Marwan Ghabril,David Goldstein,Vani Gopalreddy,Priya Grewal,Paul H. Hayashi,Jay H. Hoofnagle,Neil Kaplowitz,Suthat Liangpunsakul,Steven N. Lichtman,Lawrence Liu,Victor Navarro,Joseph A. Odin,Simona Rossi,Mark W. Russo,Thomas D. Schiano,Averell H. Sherker,Raj Vuppalanchi,Paul B. Watkins,Steven Zacks,Amanda Balasco,Kristin Chesney,Audrey Corne,Sherrie Cummings,Gale Groseclose,Alex Hammett,Judy Hooker,Varun Kesar,Sophana Mao,Kenari Marks,Regina McFadden,Yolanda Melgoza,Sherif Mikhail,Susan Milstein,Wendy Morlan,Val Peacock,Nidia Rosado,Tracy Russell,Maricruz Vega,Manisha Verma,Patricia F. Walker,Rachana Yalamanchili,Michelle McClanahan-Crowder,Katherine Galan,Tuan Chau,Kowsalya Ragavan,Hoss Rostami,Carmel Puglisi-Scharenbroich,Rebecca Torrance,Rebekah Van Raaphorst +77 more
TL;DR: In this article, the authors present characteristics and subgroup analyses from the first 1257 patients enrolled in the study, and conclude that there are no differences in outcomes of patients with short vs long latency of DILI.
Journal ArticleDOI
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Eric Lawitz,J. Lalezari,Tarek Hassanein,Kris V. Kowdley,Fred Poordad,Aasim Sheikh,Nezam H. Afdhal,David E. Bernstein,E. DeJesus,B. Freilich,David R. Nelson,Douglas T. Dieterich,Ira M. Jacobson,Donald M. Jensen,Gary A Abrams,Jama M. Darling,Maribel Rodriguez-Torres,K. Rajender Reddy,Mark S. Sulkowski,Natalie Bzowej,Robert H. Hyland,Hongmei Mo,Ming Lin,M. Mader,R. Hindes,Efsevia Albanis,William T. Symonds,M.M. Berrey,Andrew J. Muir +28 more
TL;DR: The findings lend support to the further assessment of sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks in treatment-naive patients with HCV genotype-1, and sustained virological response, defined as undetectable HCV RNA at post-treatment weeks 12 and 24.
Journal ArticleDOI
Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.
TL;DR: To optimally manage hepatitis C and associated comorbidities, patients benefit from multidisciplinary teams that can provide HCV-specific care and treatment.
Journal ArticleDOI
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.
Marie E. Faughnan,Johannes J. Mager,Steven W. Hetts,Valerie A. Palda,Kelly Lang-Robertson,Elisabetta Buscarini,Erik Deslandres,Raj S. Kasthuri,Andrea Lausman,David M. Poetker,Felix Ratjen,Mark S. Chesnutt,Marianne S. Clancy,Kevin J. Whitehead,Hanny Al-Samkari,Murali M. Chakinala,Miles Conrad,Daniel Cortes,Claudia Crocione,Jama M. Darling,Els de Gussem,Carol Derksen,Sophie Dupuis-Girod,Patrick Foy,Urban W. Geisthoff,James R. Gossage,Adrienne M. Hammill,Ketil Heimdal,Katharine J. Henderson,Vivek N. Iyer,Anette Drøhse Kjeldsen,Masaki Komiyama,Kevin Korenblatt,Jamie McDonald,Jack McMahon,Justin P. McWilliams,Mary E. Meek,Meir Mei-Zahav,Scott E. Olitsky,Sara Palmer,Rose Pantalone,Jay F. Piccirillo,Beth Plahn,Mary Porteous,Marco C. Post,Ivan Radovanovic,Paul J. Rochon,Josanna Rodriguez-Lopez,Carlo Sabbà,Marcelo M. Serra,Claire L. Shovlin,Dennis L. Sprecher,Andrew J. White,Ingrid Winship,Roberto Zarrabeitia +54 more
TL;DR: The expert panel generated and approved 6 new recommendations that highlight new evidence in existing topics from the first International HHT Guidelines and provide guidance in 3 new areas: anemia, pediatrics, and pregnancy and delivery.
Journal ArticleDOI
Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection
Mark S. Sulkowski,Hugo E. Vargas,Adrian M. Di Bisceglie,Alexander Kuo,K. Rajender Reddy,Joseph K. Lim,Giuseppe Morelli,Jama M. Darling,Jordan J. Feld,Robert S. Brown,Lynn M. Frazier,Thomas G. Stewart,Michael W. Fried,David R. Nelson,Ira M. Jacobson,Nezam H. Afdhal,Imtiaz Alam,Ziv Ben-Ari,J. Bredfeldt,R.S. Brown,R.T. Chung,J. Darling,W. Harlan,A. M. Di Bisceglie,Rolland C. Dickson,H.A. Elbeshbeshy,Gregory T. Everson,Jordan J. Feld,Jonathan M. Fenkel,M.W. Fried,Joseph S. Galati,S.C. Gordon,Mohamed Hassan,T.N. Hawkins,Federico Hinestrosa,I.M. Jacobson,C.A. Kerr,A. Kuo,P. Kwo,Josh Levitsky,J. Lim,A.S. Lok,Mark E. Mailliard,Michael P. Manns,G. Morelli,Andrew J. Muir,D. Nelson,Jacqueline G. O'Leary,Brian L. Pearlman,P. Pockros,Ananthakrishnan Ramani,Nancy Reau,K.R. Reddy,Eugene R. Schiff,Kenneth E. Sherman,Mitchell L. Shiffman,Coleman Smith,J.R. Spivey,Richard K. Sterling,M.S. Sulkowski,Gyongyi Szabo,Norah A. Terrault,C. Trautwein,H.E. Vargas,K. Watts,A. Williams,Stefan Zeuzem +66 more
TL;DR: In a large prospective observational cohort study, a 12-week regimen of simeprevir plus sofosbuvir was associated with high rates of sustained virologic response (SVR) and infrequent treatment discontinuation.